GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (NAS:FBIO) » Definitions » Price-to-Owner-Earnings

Fortress Biotech (Fortress Biotech) Price-to-Owner-Earnings : (As of Apr. 27, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Fortress Biotech Price-to-Owner-Earnings?

As of today (2024-04-27), Fortress Biotech's share price is $1.72. Fortress Biotech does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Fortress Biotech's Price-to-Owner-Earnings or its related term are showing as below:


FBIO's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.385
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-27), Fortress Biotech's share price is $1.72. Fortress Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.22. Therefore, Fortress Biotech's PE Ratio for today is At Loss.

As of today (2024-04-27), Fortress Biotech's share price is $1.72. Fortress Biotech's EPS without NRI for the trailing twelve months (TTM) ended in was $-8.49. Therefore, Fortress Biotech's PE Ratio without NRI for today is At Loss.


Fortress Biotech Price-to-Owner-Earnings Historical Data

The historical data trend for Fortress Biotech's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech Price-to-Owner-Earnings Chart

Fortress Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Fortress Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Fortress Biotech's Price-to-Owner-Earnings

For the Biotechnology subindustry, Fortress Biotech's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Price-to-Owner-Earnings falls into.



Fortress Biotech Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Fortress Biotech's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.72/-6.68
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fortress Biotech  (NAS:FBIO) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Fortress Biotech Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortress Biotech (Fortress Biotech) Business Description

Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
Executives
Rosenwald Lindsay A Md director, 10 percent owner, officer: PRESIDENT, CEO & CHAIRMAN 375 PARK AVE, NEW YORK NY 10152
Lucy Lu director THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
David Jin officer: Chief Financial Officer C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036
Dov Klein director C/O FORTRESS BIOTECH, INC., 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
Robyn Hunter officer: Chief Financial Officer 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eric K Rowinsky director IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Malcolm Hoenlein director 750 LEXINGTON AVENUE, NEW YORK NY 10022
Michael S Weiss director, 10 percent owner, officer: EXECUTIVE VICE CHAIRMAN 750 LEXINGTON AVE, NEW YORK NY 10022
J Jay Lobell director 365 W END AVE, APARTMENT 10A, NEW YORK NY 10024
Jimmie Harvey director 3741 EAST FAIRWAY DRIVE, BIRMINGHAM AL 35213
Kevin Lorenz director C/O NUVEEN, 333 W. WACKER DR., CHICAGO IL 60606
George Avgerinos officer: SVP, Biologics Operations C/O CORONADO BIOSCIENCES, INC., 24 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Kevin Horgan other: Former Chief Medical Officer C/O SOLIGENIX, INC., 29 EMMONS DRIVE, STE. C-10, PRINCETON NJ 08540
David Jonathan Barrett director ONE PENN PLAZA, SUITE 2514, NEW YORK NY 10119
Harlan F Weisman director C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803

Fortress Biotech (Fortress Biotech) Headlines

From GuruFocus